Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

This study collects long-term safety data on a drug called pirtobrutinib in people with blood cancers (such as certain types of leukemia or lymphoma) who are already taking it in a separate, related clinical trial. It is an extension study designed to keep track of how safe the drug is over a longer period. **You may be eligible if...** - You are already enrolled and actively receiving pirtobrutinib in the originator study (JZNJ) - You agree to follow contraception requirements during the study **You may NOT be eligible if...** - You are pregnant, planning to become pregnant, or breastfeeding during the study or shortly after stopping treatment Note: This is a continuation study. You must already be enrolled in the related trial to participate. Talk to your doctor to see if this trial is right for you.